Procept Completes Phase I Clinical Program for PRO 2000 Gel.CAMBRIDGE, Mass.--(BW HealthWire)--Oct. 21, 1997-- Antiviral gel well tolerated in Antwerp and London clinical trials Procept Inc. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on :PRCT PRCT Practice PRCT Prospective, Randomized, Controlled Trial (medicine) PRCT Partial Rotator Cuff Tear ) today announced the completion of its second Phase I safety trial in London, United Kingdom with the company's lead drug candidate, PRO 2000 Gel. The product is designed to be used for the prevention of human immunodeficiency virus human immunodeficiency virus n. HIV. Human immunodeficiency virus (HIV) A transmissible retrovirus that causes AIDS in humans. type 1 (HIV-1) infection and other sexually transmitted diseases Sexually transmitted diseases Infections that are acquired and transmitted by sexual contact. Although virtually any infection may be transmitted during intimate contact, the term sexually transmitted disease is restricted to conditions that are largely (STDs). Initial review of the Phase I data indicates PRO 2000 Gel was well tolerated in healthy women. The double-blind study double-blind study, n experimental technique in clinical research in which neither the researcher nor the patient knows whether the treatment administered is considered inactive (placebo) or active (medicinal). , conducted at St. Mary's Hospital in London, involved 36 healthy female volunteers who administered either PRO 2000 Gel or a placebo gel intravaginally for up to two weeks. No serious adverse events were reported. A detailed analysis of the data is underway. In June, Procept announced the completion of its first Phase I clinical trial Noun 1. phase I clinical trial - a clinical trial on a few persons to determine the safety of a new drug or invasive medical device; for drugs, dosage or toxicity limits should be obtained phase I of PRO 2000 Gel at the Institute of Tropical Medicine in Antwerp, Belgium. On October 22, Dr. Lut Van Damme, one of the principal investigators, will present unblinded data from the Antwerp trial at the International Congress of Sexually Transmitted Diseases in Seville, Spain. Results from this study also indicate that PRO 2000 Gel is safe and well tolerated in healthy women. "The successful completion of the Phase I clinical program allows us to focus on the design and implementation of Phase II safety trials involving sexually active couples," said Stanley C. Erck, president and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. . "The safety and tolerance data gathered in these studies should enable us to move quickly into Phase II/III trials in collaboration with world health agencies." Procept Inc. is engaged in the research and development of small molecule therapeutics for the prevention and treatment of chronic and life-threatening immune system disorders. Procept is developing therapeutics for the treatment of autoimmune diseases, organ transplant rejection and infectious diseases, such as AIDS and tuberculosis. Founded in 1985 and traded on the Nasdaq National Market System under the symbol PRCT, Procept is located in Cambridge, Mass. CONTACT: Procept Inc. Stanley C. Erck, 617/491-1100 or INFOCUS Inc. Karen M. Goldman, 609/683-9055 |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion